2298 | Humans |
1353 | Parkinson disease |
1337 | Male |
1282 | Female |
994 | Middle Aged |
991 | Aged |
812 | Human |
700 | Animals |
638 | Parkinson Disease (physiopathology) |
637 | Nervous system diseases |
499 | Adult |
464 | Parkinson Disease (drug therapy) |
326 | Parkinson Disease (complications) |
290 | Parkinson Disease (metabolism) |
290 | Aged, 80 and over |
285 | Treatment |
279 | Parkinson Disease (pathology) |
251 | Parkinson Disease (therapy) |
244 | Parkinson Disease (diagnosis) |
215 | Parkinson's disease |
210 | Animal |
201 | Parkinson Disease (genetics) |
199 | Dopamine |
193 | Antiparkinson Agents (therapeutic use) |
188 | Parkinson Disease (psychology) |
179 | Levodopa (therapeutic use) |
173 | Rats |
167 | Case-Control Studies |
166 | Dopamine (metabolism) |
154 | Treatment Outcome |
152 | Disease Models, Animal |
150 | Mice |
144 | Severity of Illness Index |
143 | Parkinson Disease (epidemiology) |
140 | Chemotherapy |
139 | Levodopa |
132 | Time Factors |
128 | Antiparkinson agent |
125 | Rat |
124 | Neuropsychological Tests |
122 | Brain (metabolism) |
117 | Brain (pathology) |
114 | Parkinson Disease (surgery) |
114 | Degenerative disease |
113 | Parkinson Disease, Secondary (chemically induced) |
112 | Parkinson Disease (diagnostic imaging) |
112 | Dyskinesia |
111 | Levodopa (adverse effects) |
105 | Exploration |
105 | Corpus striatum |
104 | Antiparkinson Agents (adverse effects) |
101 | Risk Factors |
101 | Follow-Up Studies |
101 | Brain (physiopathology) |
98 | Review |
98 | Disease Progression |
98 | Canada |
97 | Analysis of Variance |
95 | Toxicity |
94 | Parkinson Disease (etiology) |
91 | Magnetic Resonance Imaging |
90 | Basal ganglion |
87 | Monkey |
86 | Alzheimer disease |
83 | Immunohistochemistry |
83 | Deep Brain Stimulation (methods) |
82 | Subthalamic nucleus |
80 | Retrospective Studies |
79 | Adolescent |
75 | Neurons (metabolism) |
74 | Tomography, Emission-Computed |
74 | Emission tomography |
73 | Parkinsonism |
73 | Corpus Striatum (metabolism) |
73 | Cognition |
72 | Cohort Studies |
71 | Deep brain stimulation |
70 | Dose-Response Relationship, Drug |
70 | Comparative study |
69 | Macaca fascicularis |
68 | Reproducibility of Results |
68 | Mutation |
67 | Psychomotor Performance (physiology) |
66 | Tremor |
66 | Prevalence |
66 | Movement (physiology) |
64 | Surgery |
64 | Rats, Sprague-Dawley |
64 | Animal model |
62 | Neurons (physiology) |
62 | Encephalon |
62 | Age Factors |
61 | Pathogenesis |
59 | Wolff Parkinson White syndrome |
59 | Pathophysiology |
59 | Elderly |
59 | Double-Blind Method |
59 | Dopamine (physiology) |
58 | Electrocardiography |
58 | Brain (vertebrata) |
56 | Wolff-Parkinson-White Syndrome (physiopathology) |
56 | Pallidum |
56 | Mouse |
55 | Locus niger |
55 | Electromyography |
54 | Wolff-Parkinson-White Syndrome (surgery) |
54 | Surveys and Questionnaires |
54 | Substantia Nigra (pathology) |
54 | Prognosis |
54 | Neurons (drug effects) |
54 | Child |
52 | Quality of Life |
52 | Mice, Inbred C57BL |
52 | D2 Dopamine receptor |
52 | Cognitive disorder |
52 | Cognition Disorders (etiology) |
51 | Cells, Cultured |
51 | Brain Mapping |
51 | Behavior |
50 | Diagnosis, Differential |
49 | Tremor (physiopathology) |
49 | Positron emission tomography |
49 | Experimental disease |
49 | Brain (diagnostic imaging) |
49 | Agonist |
48 | Molecular Sequence Data |
48 | Models, Biological |
48 | Dopaminergic neuron |
47 | Reference Values |
47 | Prospective Studies |
47 | Nuclear magnetic resonance imaging |
47 | Neurotoxin |
47 | Neurons (pathology) |
47 | Globus Pallidus (surgery) |
47 | Complication |
46 | alpha-Synuclein (metabolism) |
46 | Parkinson Disease, Secondary (physiopathology) |
46 | Diagnosis |
46 | Brain (drug effects) |
45 | Neuron |
45 | Levodopa (pharmacology) |
45 | Dopamine agonist |
45 | Dementia |
45 | Corpus Striatum (drug effects) |
45 | Antiparkinson Agents (pharmacology) |
44 | Positron-Emission Tomography |
44 | Electrodiagnosis |
44 | Dyskinesia, Drug-Induced (physiopathology) |
43 | Positron |
43 | Central nervous system |
42 | Subthalamic Nucleus (physiology) |
42 | Mutation (genetics) |
42 | Motor control |
42 | Dopamine Agents (therapeutic use) |
41 | Reaction Time (physiology) |
41 | Magnetic Resonance Imaging (methods) |
41 | Antiparkinson Agents (administration & dosage) |
41 | Amino Acid Sequence |
41 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
40 | Motor Activity (drug effects) |
40 | Globus Pallidus (physiopathology) |
40 | Case study |
39 | Subthalamic Nucleus (physiopathology) |
39 | Substantia Nigra (drug effects) |
39 | Risk factor |
39 | Protein-Serine-Threonine Kinases (genetics) |
39 | Predictive Value of Tests |
39 | Phenotype |
39 | Genotype |
39 | Disability Evaluation |
39 | Cross-Sectional Studies |
39 | Arrhythmia |
38 | Young Adult |
38 | Electrophysiology |
38 | Cardiovascular disease |
38 | Biomechanical Phenomena |
38 | Behavior, Animal (drug effects) |
37 | United States |
37 | Sensitivity and Specificity |
37 | Longitudinal Studies |
37 | Depression |
37 | Alzheimer Disease (pathology) |
37 | Algorithms |
36 | Tyrosine 3-Monooxygenase (metabolism) |
36 | Levodopa (administration & dosage) |
36 | Image Processing, Computer-Assisted |
36 | Epidemiology |
36 | Dopamine receptor |
36 | Body movement |
35 | dopamine |
35 | Technique |
35 | Psychiatric Status Rating Scales |
35 | Parkinson Disease, Secondary (pathology) |
35 | Mechanism of action |
35 | Long term |
35 | Dyskinesia, Drug-Induced (etiology) |
35 | Cognition Disorders (diagnosis) |
35 | Autoradiography |
34 | Tremor (etiology) |
34 | Posture |
34 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
34 | Dihydroxyphenylalanine (analogs & derivatives) |
34 | Deep Brain Stimulation |
34 | Corpus Striatum (diagnostic imaging) |
34 | Clinical Trials as Topic |
34 | Age of Onset |
34 | Activities of Daily Living |
33 | Ubiquitin-Protein Ligases (metabolism) |
33 | Oxidative stress |
33 | Mice, Knockout |
33 | Genetics |
33 | Functional Laterality (physiology) |
33 | Electroencephalography |
33 | Drug Therapy, Combination |
33 | Alzheimer Disease (metabolism) |
32 | Substantia Nigra (physiopathology) |
32 | Psychomotor Performance |
32 | Parkinson Disease, Secondary (metabolism) |
32 | Parkinson Disease (rehabilitation) |
32 | Oxidopamine |
32 | Neuroprotective Agents (therapeutic use) |
32 | Dopamine Agonists (therapeutic use) |
32 | Dopa |
32 | Degeneration |
31 | deep brain stimulation |
31 | Ubiquitin-Protein Ligases (genetics) |
31 | Psychotropic |
31 | Positron-Emission Tomography (methods) |
31 | Parkinson Disease, Secondary (drug therapy) |
31 | Parkinson Disease (enzymology) |
31 | Instrumentation therapy |
31 | Dopamine Agents (pharmacology) |
31 | Canada (epidemiology) |
30 | alpha-Synuclein (genetics) |
30 | Substantia Nigra (metabolism) |
30 | Sleep disorder |
30 | Psychomotor Performance (drug effects) |
30 | Neural Pathways (physiopathology) |
30 | Motor system disorder |
30 | Motor Activity (physiology) |
30 | Genetic Predisposition to Disease |
30 | Functional Laterality |
30 | Electrodes, Implanted |
30 | Dementia (pathology) |
30 | Corpus Striatum (physiopathology) |
30 | Basal Ganglia (physiopathology) |
29 | Wolff-Parkinson-White Syndrome (diagnosis) |
29 | Thalamus |
29 | Sex Factors |
29 | Models |
29 | Inflammation |
29 | Incidence |
29 | In vitro |
29 | Electrical stimulus |
29 | Brain |
28 | Rapid eye movement sleep |
28 | Psychosis |
28 | Neurologic Examination |
28 | Mitochondria (metabolism) |
28 | Mice, Transgenic |
28 | Lesion |
28 | Huntington disease |
28 | Heart Conduction System (physiopathology) |
28 | Gait Disorders, Neurologic (etiology) |
28 | Corpus Striatum (pathology) |
28 | Autopsy |
27 | Statistics, Nonparametric |
27 | Neuroprotective Agents (pharmacology) |
27 | Motor Cortex (physiopathology) |
27 | Models, Neurological |
27 | Idiopathic |
27 | Gait |
27 | Evolution |
27 | Dopaminergic Neurons (metabolism) |
27 | Cell Line |
27 | Apoptosis |
26 | Transplantation |
26 | Pilot Projects |
26 | Nigrostriatal pathway |
26 | Microelectrodes |
26 | Metabolism |
26 | Dopamine Plasma Membrane Transport Proteins (metabolism) |
26 | D1 Dopamine receptor |
26 | Adenosine (metabolism) |
26 | Action Potentials (physiology) |
26 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology) |
25 | Senescence |
25 | Schizophrenia |
25 | Putamen (metabolism) |
25 | Phylogeny |
25 | Pathology |
25 | Movement Disorders (physiopathology) |
25 | Motor Activity |
25 | Electric Stimulation Therapy |
25 | Dystonia |
25 | Dopamine Agonists (pharmacology) |
25 | Cognition (physiology) |
24 | Stereotaxic Techniques |
24 | REM Sleep Behavior Disorder (diagnosis) |
24 | Public health |
24 | Posture (physiology) |
24 | Motricity |
24 | Instrumental stimulation |
24 | Guam Parkinson dementia |
24 | Dyskinesia, Drug-Induced (metabolism) |
24 | Dyskinesia, Drug-Induced (drug therapy) |
24 | Dementia (etiology) |
23 | dyskinesia |
23 | Randomized Controlled Trials as Topic |
23 | Protein Binding |
23 | Primates |
23 | Polysomnography |
23 | Neural Pathways (physiology) |
23 | Memory |
23 | Environment |
23 | Dopamine Agonists (adverse effects) |
23 | Dopamine Agents (adverse effects) |
23 | Comorbidity |
23 | Cell death |
23 | Brain (physiology) |
23 | Base Sequence |
23 | Astrocyte |
23 | Antipsychotic Agents (therapeutic use) |
22 | Receptors, Dopamine (drug effects) |
22 | Raclopride |
22 | REM Sleep Behavior Disorder (complications) |
22 | Postural Balance (physiology) |
22 | Pedigree |
22 | Lewy Bodies (pathology) |
22 | Kinetics |
22 | Etiology |
22 | Cerebral Cortex (physiopathology) |
22 | Cell Line, Tumor |
22 | Blotting, Western |
22 | Astrocytes (metabolism) |
22 | Antipsychotic Agents (adverse effects) |
22 | Amyotrophic lateral sclerosis |
21 | Treatment efficiency |
21 | Symptomatology |
21 | Signal Transduction |
21 | Receptors, Dopamine (metabolism) |
21 | RNA, Messenger (metabolism) |
21 | Parkinson Disease (classification) |
21 | Oxidative Stress |
21 | Ontario |
21 | Movement Disorders (etiology) |
21 | Motor Cortex (physiology) |
21 | Heart Conduction System (surgery) |
21 | Gene expression |
21 | Gait Disorders, Neurologic (physiopathology) |
21 | Fluorine Radioisotopes |
21 | Biological activity |
21 | Basal Ganglia (pathology) |
21 | Alzheimer Disease (diagnosis) |
21 | Accessory bundle |
20 | rat |
20 | Wolff-Parkinson-White Syndrome (complications) |
20 | Regression Analysis |
20 | Psychometrics |
20 | Parkinson Disease (mortality) |
20 | Neuroprotective agent |
20 | Movement |
20 | Mitochondria |
20 | Microelectrode |
20 | History, 20th Century |
20 | Gait (physiology) |
20 | Executive function |
20 | Dopamine Plasma Membrane Transport Proteins |
20 | Data Interpretation, Statistical |
20 | Brain Mapping (methods) |
20 | Attention |
19 | Walking |
19 | REM Sleep Behavior Disorder (physiopathology) |
19 | Putamen |
19 | Prevention |
19 | Placebo Effect |
19 | Photic Stimulation |
19 | Parkinson Disease |
19 | Parkinson Disease (blood) |
19 | Neuroleptic |
19 | Movement (drug effects) |
19 | Midbrain |
19 | Lewy body |
19 | Iron |
19 | Gene Expression Regulation |
19 | Electric Stimulation |
19 | Catecholamine |
19 | Biological receptor |
19 | Alzheimer Disease (physiopathology) |
18 | levodopa |
18 | Vision |
18 | Statistics as Topic |
18 | Signal Transduction (physiology) |
18 | Selegiline (therapeutic use) |
18 | Reward |
18 | Reaction Time |
18 | Protein Kinases (genetics) |
18 | Pregnancy |
18 | Perception |
18 | Parkinson Disease (immunology) |
18 | Muscle, Skeletal (physiopathology) |
18 | Medical screening |
18 | MPTP |
18 | Learning |
18 | In vivo |
18 | HEK293 Cells |
18 | Gene |
18 | Evoked Potentials, Motor (physiology) |
18 | Dyskinesia, Drug-Induced (prevention & control) |
18 | Drug Combinations |
18 | Dementia (diagnosis) |
18 | Dementia (complications) |
18 | Cognition Disorders (physiopathology) |
18 | Cerebral disorder |
18 | Cell Count |
18 | Cardiac Pacing, Artificial |
18 | Binding Sites |
18 | Alzheimer's disease |
17 | Tremor (therapy) |
17 | Tomography, Emission-Computed, Single-Photon |
17 | Thalamus (physiopathology) |
17 | Task Performance and Analysis |
17 | Syndrome |
17 | Stereotaxic surgery |
17 | Risk |
17 | Reverse Transcriptase Polymerase Chain Reaction |
17 | Receptors, Dopamine D2 (metabolism) |
17 | Receptors, Dopamine (physiology) |
17 | Radionuclide study |
17 | Quebec |
17 | Protein Structure, Tertiary |
17 | Protein Kinases (metabolism) |
17 | Proportional Hazards Models |
17 | Postoperative Complications |
17 | Phosphorylation |
17 | Parkinson’s disease |
17 | Parkinsonian Disorders (physiopathology) |
17 | Oscillation |
17 | Neuroprotection |
17 | Neurodegenerative Diseases (pathology) |
17 | Nerve Tissue Proteins |
17 | Motor cortex |
17 | Motor Skills (physiology) |
17 | Memory (physiology) |
17 | Membrane Glycoproteins |
17 | Infant |
17 | In Vitro Techniques |
17 | Dopaminergic pathway |
17 | Depression (etiology) |
17 | DNA Mutational Analysis |
17 | Cues |
17 | Computer Simulation |
17 | Chronic |
17 | Catheter Ablation |
17 | Carbidopa (therapeutic use) |
17 | Antagonist |
17 | Aging (physiology) |
16 | genetics |
16 | Tremor (diagnosis) |
16 | Thioinosine (analogs & derivatives) |
16 | Subthalamic Nucleus (surgery) |
16 | Signal Processing, Computer-Assisted |
16 | Sensitivity |
16 | Reactive Oxygen Species (metabolism) |
16 | Rats, Long-Evans |
16 | Radiopharmaceuticals |
16 | Parkinson Disease (prevention & control) |
16 | Pain |
16 | Oral administration |
16 | Nerve Tissue Proteins (genetics) |
16 | Movement Disorders (therapy) |
16 | Models, Statistical |
16 | Modeling |
16 | Memory disorder |
16 | Membrane Transport Proteins |
16 | Logistic Models |
16 | Locomotion |
16 | Involuntary movement |
16 | Glutamate receptor |
16 | Genetic Predisposition to Disease (genetics) |
16 | Extrapyramidal syndrome |
16 | Electrodes |
16 | Dysfunction |
16 | Drug Administration Schedule |
16 | Drosophila Proteins (genetics) |
16 | Dopaminergic Neurons (pathology) |
16 | Deep Brain Stimulation (adverse effects) |
16 | Clinical trial |
16 | Cerebral Cortex (pathology) |
16 | Cell Survival |
16 | Caudate Nucleus (metabolism) |
16 | Catheter Ablation (methods) |
16 | Carbon Radioisotopes |
16 | Brain Chemistry |
16 | Basal Ganglia (physiology) |
16 | Basal Ganglia (metabolism) |
16 | Attention (physiology) |
16 | Alzheimer Disease (drug therapy) |
15 | parkinsonism |
15 | basal ganglia |